These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 35869443

  • 1. Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation.
    Lowe M, Murray L, Tyagi A, Gorrie G, Miller S, Dani K, NHS Greater Glasgow and Clyde Headache Service.
    J Headache Pain; 2022 Jul 22; 23(1):86. PubMed ID: 35869443
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Impact of a reimbursement policy change on treatment with erenumab in migraine - a real-world experience from Germany.
    Hong JB, Lange KS, Fitzek M, Overeem LH, Triller P, Siebert A, Reuter U, Raffaelli B.
    J Headache Pain; 2023 Oct 30; 24(1):144. PubMed ID: 37899428
    [Abstract] [Full Text] [Related]

  • 4. Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine.
    Robblee J, Devick KL, Mendez N, Potter J, Slonaker J, Starling AJ.
    Headache; 2020 Oct 30; 60(9):2014-2025. PubMed ID: 32920850
    [Abstract] [Full Text] [Related]

  • 5. Erenumab in highly therapy-refractory migraine patients: First German real-world evidence.
    Scheffler A, Messel O, Wurthmann S, Nsaka M, Kleinschnitz C, Glas M, Naegel S, Holle D.
    J Headache Pain; 2020 Jul 03; 21(1):84. PubMed ID: 32620151
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis.
    Andreou AP, Fuccaro M, Hill B, Murphy M, Caponnetto V, Kilner R, Lambru G.
    J Headache Pain; 2022 Nov 04; 23(1):139. PubMed ID: 36333710
    [Abstract] [Full Text] [Related]

  • 10. Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials.
    Tepper SJ, Ashina M, Reuter U, Hallström Y, Broessner G, Bonner JH, Picard H, Cheng S, Chou DE, Zhang F, Klatt J, Mikol DD.
    J Headache Pain; 2021 Jul 23; 22(1):81. PubMed ID: 34301173
    [Abstract] [Full Text] [Related]

  • 11. Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17-30 months.
    Troy E, Shrukalla AA, Buture A, Conaty K, Macken E, Lonergan R, Melling J, Long N, Shaikh E, Birrane K, Tomkins EM, Goadsby PJ, Ruttledge MH.
    J Headache Pain; 2023 Jan 16; 24(1):5. PubMed ID: 36647006
    [Abstract] [Full Text] [Related]

  • 12. Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience.
    Russo A, Silvestro M, Scotto di Clemente F, Trojsi F, Bisecco A, Bonavita S, Tessitore A, Tedeschi G.
    J Headache Pain; 2020 Jun 09; 21(1):69. PubMed ID: 32517693
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study.
    Cullum CK, Do TP, Ashina M, Bendtsen L, Hugger SS, Iljazi A, Gusatovic J, Snellman J, Lopez-Lopez C, Ashina H, Amin FM.
    J Headache Pain; 2022 Jun 02; 23(1):61. PubMed ID: 35655137
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry study.
    Lanteri-Minet M, Fabre R, Martin C, Pradat K, Alchaar A, Bozzolo E, Duchene ML, Van Obberghen EK, Donnet A, Fontaine D.
    J Headache Pain; 2023 Nov 08; 24(1):152. PubMed ID: 37940860
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.